Insmed CEO to Present at Drug Discovery & Development ... ( CEO Geoffrey Allan Will Discuss Com...)

Insmed CEO to Present at Drug Discovery & Development Conference

Date:7/25/2008

CEO Geoffrey Allan Will Discuss Company's IPLEX(TM) Program in Myotonic

Muscular Dystrophy

RICHMOND, Va., July 25 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM) a developer of follow-on biologics and biopharmaceuticals, today announced that Geoffrey Allan, Ph.D., CEO of Insmed, will present at IBC's 13th Annual Drug Discovery and Development of Innovative Therapeutics on Thursday, August 7th, 2008 at 9:25 AM ET.

Dr. Allan will be participating in the Orphan Diseases track of the conference and his presentation will be entitled, "Myotonic Muscular Dystrophy - A Major Unmet Medical Need." He will present Insmed's progress with its Phase II trial for IPLEX(TM) in Myotonic Muscular Dystrophy. The trial, which has seen strong patient and physician interest, is now fully enrolled. It is a six month, randomized, double-blind, placebo-controlled trial being conducted at 13 research centers across the U.S.

The conference will be held from August 4th to August 7th, 2008, at the World Trade Center Boston and the Seaport Hotel in Boston, MA.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, strategic alternatives, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause act
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related biology technology :

1. Insmed to Host Second Quarter 2008 Conference Call
2. Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor
3. Insmed Retains RBC Capital Markets as Strategic Financial Advisor
4. Insmed to Present at Collins Stewart Fourth Annual Growth Conference
5. Insmed to Request Hearing Before NASDAQ Panel to Review NASDAQ Staff Determination
6. Insmed Announces First Quarter 2008 Financial Results
7. Insmed to Present at CBI Follow-On Biologics Conference
8. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
11. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market

Post Your Comments:

(Date:11/30/2009)...HUN, China and LOS ANGELES, Nov. 30 /PRNewswire-As...c. (OTC Bulletin Board: CYXN; ,China Yongxin,Pharm...rer, distributor and,retailer of pharmaceuticals i...eted preparation for distribution of medicines on ...vernment recently formalized the nation,s Essentia...

(Date:11/30/2009)..., Nov. 30 BioMarin Pharm...at the Food and Drug Administration (FDA) has gran...e (3,4-DAP), amifampridine phosphate, for the rare...ome (LEMS). 3,4-DAP has previously received orpha...009, the Committee for Medicinal Products for Huma...

(Date:11/30/2009)..., Nov. 30 Cell Therapeut...oday that its new class of platinum-based anti-tum...a stronger anti-tumor potency and activity compare...as well as the ability to overcome cisplatin-resis...ented in a paper titled "Novel Bis-platinum Comple...

(Date:11/30/2009)...GHAI, Nov. 30 /PRNewswire-Asia/ -- WuXi PharmaTech...ology, and medical-device research and,development...the United States,announced that it had been sele... list for the fifth consecutive year. The list rec...s technology, media, and telecommunications,indust...

Breaking Biology Technology:China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 2 China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 3 FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2 FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3 FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4 New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2 New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3 WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year 2

[0] China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List [0] FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS [0] New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents [0] WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year

... Svenja Goth , PerkinElmer Life and...enue , Shelton, CT 06484-4794 USA , ...ytical Sciences Department , Physical Ch...es Guesde , 94403 Vitry-sur-Seine - FRAN... Separation of transitions , Detec...

...xpression Assays average 100% efficiency (+/- 10%)...ms has designed and manufactured over 40,000 real-...nes in humans, mice, and rats. TaqMan Gene Express...forward and reverse) and a fluorescent labeled Taq... One of the major user concerns regarding any r...

... In this application note, several different ... for their merits. A comprehensive examination of ...y modes was performed to illustrate data quality a...r of metabolites were found with each mode of oper...tabolites derived from glyburide. , Overv...

Other Biology Technology:Practical Applications of HyperDSC in a Pharmaceutical Laboratory 2 Practical Applications of HyperDSC in a Pharmaceutical Laboratory 3 Practical Applications of HyperDSC in a Pharmaceutical Laboratory 4 Practical Applications of HyperDSC in a Pharmaceutical Laboratory 5 Amplification Efficiency of TaqMan Gene Expression Assays 2 Amplification Efficiency of TaqMan Gene Expression Assays 3 Amplification Efficiency of TaqMan Gene Expression Assays 4 Amplification Efficiency of TaqMan Gene Expression Assays 5 Amplification Efficiency of TaqMan Gene Expression Assays 6 Amplification Efficiency of TaqMan Gene Expression Assays 7 Amplification Efficiency of TaqMan Gene Expression Assays 8 Strategies to Identify and Confirm Phase I Metabolites of Glyburide Using the 4000 Q TRAP System 2 Strategies to Identify and Confirm Phase I Metabolites of Glyburide Using the 4000 Q TRAP System 3 Strategies to Identify and Confirm Phase I Metabolites of Glyburide Using the 4000 Q TRAP System 4 Strategies to Identify and Confirm Phase I Metabolites of Glyburide Using the 4000 Q TRAP System 5 Strategies to Identify and Confirm Phase I Metabolites of Glyburide Using the 4000 Q TRAP System 6

Practical Applications of HyperDSC in a Pharmaceutical Laboratory Amplification Efficiency of TaqMan Gene Expression Assays Strategies to Identify and Confirm Phase I Metabolites of Glyburide Using the 4000 Q TRAP System

(Date:11/30/2009)...ase is available in German . , The DFG has ... Research Centres as of 1 January 2010. This decis...ttee in Bonn. The new centres will initially be fu...n addition, 20 percent overhead funding for indire...he centres, research topics range from modern pros...

(Date:11/30/2009)...s of The Journal of Experimental Biology are ple... National de la Recherche Scientifique (CNRS) in t...r of this year,s JEB Outstanding Paper Prize. ,T...ng achievement and is intended to encourage young ...-in-Chief, and adds that ,we truly appreciate when...

(Date:11/30/2009)...temperatures continue to rise scientists are prese...ow species respond and adapt. In a paper published...sco Rodriguez-Trelles and Dr Miguel Rodriguez asse...rming of approximately 0.6˚C has already affe... facing ecologists and evolutionary biologists is ...

[0] DFG approves funding for 17 new collaborative research centers [1] French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 [0] How can scientists measure evolutionary responses to climate change?

...l engineers at The University of Texas Health Scie...ion initiative to produce a bio-compatible compoun...esearchers have been awarded $5.2 million in initi...develop "fracture putty" that could be used to reg... explosive devices. This type of injury is called ...

... Through work originally designed to remove conta...nt of Energy,s (DOE) Brookhaven National Laborator...ty have identified plant-associated microbes that ...dings, published in the February 1, 2009 issue of ... scientists design strategies for sustainable biof...

...rt today that the FDA has approved the first human...tervention raises important ethical considerations... at issue is an embryonic stem cell-based interven...e ethics of embryo research surround the interest ...ing the first human trial of its kind. Any "first...

Other Biology News:UT to develop fracture putty for traumatic leg injuries 2 UT to develop fracture putty for traumatic leg injuries 3 UT to develop fracture putty for traumatic leg injuries 4 Scientists identify bacteria that increase plant growth 2 Scientists identify bacteria that increase plant growth 3

UT to develop fracture putty for traumatic leg injuries Scientists identify bacteria that increase plant growth Director of Berman Institute comments on FDA Approval of first human embryonic stem cell trial

Rabbit Anti-Uncoupling Protein-2, aa 144-157 Polyclonal Antibody, Unconjugated from Calbiochem

...n translation initiation. PHAS-II is highest in li...mRNA cap-binding protein, and inhibit translation ...ion in the appropriate site(s) promotes dissociati... bind to eIF-4G (p220), thereby increasing the amo...

Human GCP-2, Unconjugated from CHEMICON

Corning Culture Flask, 150 cm2, Tc-Treated, Angled Neck, Phenolic-Style, Sterile from Sigma-Aldrich

Biology Products:

Rabbit Anti-Uncoupling Protein-2, aa 144-157 Polyclonal Antibody, Unconjugated from Calbiochem Rabbit Anti-Human PHAS-II Polyclonal Antibody, Unconjugated from Lab Vision Human GCP-2, Unconjugated from CHEMICON Corning Culture Flask, 150 cm2, Tc-Treated, Angled Neck, Phenolic-Style, Sterile from Sigma-Aldrich

Insmed CEO to Present at Drug Discovery & Development ...( CEO Geoffrey Allan Will Discuss Com...)